Last reviewed · How we verify
IBI351 combined with cetuximab β — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
IBI351 combined with cetuximab β (IBI351 combined with cetuximab β) — Guangdong Association of Clinical Trials.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| IBI351 combined with cetuximab β TARGET | IBI351 combined with cetuximab β | Guangdong Association of Clinical Trials | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- IBI351 combined with cetuximab β CI watch — RSS
- IBI351 combined with cetuximab β CI watch — Atom
- IBI351 combined with cetuximab β CI watch — JSON
- IBI351 combined with cetuximab β alone — RSS
Cite this brief
Drug Landscape (2026). IBI351 combined with cetuximab β — Competitive Intelligence Brief. https://druglandscape.com/ci/ibi351-combined-with-cetuximab. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab